Last reviewed · How we verify
NCT01553474
Blood and Saliva Sample Collection for AREDS 2
trial in Age-Related Macular Degeneration in 56 participants. Completed in 5 February 2013.
Quick facts
| Lead sponsor | National Eye Institute (NEI) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 56 |
| Start date | 24 February 2012 |
| Estimated completion | 5 February 2013 |
| Sites | 1 location across United States |
Conditions studied
- Age-Related Macular Degeneration — all drugs for Age-Related Macular Degeneration →
- Eye Diseases — all drugs for Eye Diseases →
Sponsor
National Eye Institute (NEI)
Who can join
Adults 55 to 85, any sex, with Age-Related Macular Degeneration or Eye Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: \- The Age-Related Eye Disease Study 2 (AREDS 2) is looking at different eye diseases. Study participants will provide blood and saliva samples. The samples will be stored for research on eye diseases. Objectives: \- To collect blood and saliva samples for AREDS 2 research. Eligibility: \- AREDS 2 research study participants. Design: * Participants will provide blood and saliva samples. * The samples will be submitted with personal and medical information. This information will be collected during the AREDS 2 procedures.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01553474
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Age-Related Macular Degeneration
Currently open trials in the same condition.
- NCT07440225 — A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) · Phase 2, PHASE3 · recruiting
- NCT06619405 — AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance · NA · recruiting
- NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
- NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
- NCT06662162 — Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration · NA · recruiting
Other National Eye Institute (NEI) trials
Trials by the same sponsor.
- NCT06491615 — National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and · recruiting
- NCT04289571 — Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease · Phase 1 · recruiting
- NCT04833361 — Potential Environmental Causes of Uveal Coloboma · completed
- NCT06670989 — Training to Modify Fixational Eye Movements for Optimizing Visual Performance in People With Central Vision Loss · NA · active not recruiting
- NCT04591483 — Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01553474 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Eye Institute (NEI)
- Last refreshed: 29 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01553474.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing